Tavneos plus rituximab induction aids sustained remission with AAV
In a Phase 3 trial of Tavneos (avacopan) in people with ANCA-associated vasculitis (AAV), the therapy’s effectiveness in the subgroup of patients on standard induction treatment with rituximab was similar to that of the overall study population. Reasonable safety also was seen, and sustained one-year remission was higher…